Cytomegaloviruses (CMVs) code for immunoevasins, glycoproteins that are specifically dedicated to interfere with the presentation of antigenic peptides to CD8 T cells. Nonetheless, the biological outcome is not an immune evasion of the virus, since CD8 T cells can control CMV infection even when immunoevasins are expressed. Here, we compare the processing of a protective and a nonprotective epitope derived from the same viral protein, the antiapoptotic protein M45 in the murine model. The data provide evidence to conclude that protection against CMVs critically depends on antigenic peptides generated in an amount sufficient to exhaust the inhibitory capacity of immunoevasins.
Cytomegalovirus (CMV) infection causes multiple organ disease in the immunocompromised host but is usually well controlled in the immunocompetent host. Experimental immunotherapy of CMV infection by adoptive cell transfer revealed a protective function of virus-specific CD8 T cells in the model of murine CMV (mCMV) infection (11, 14) as well as in clinical trials of a cytoimmunotherapy of human CMV infection (4, 19, 24, 28) . Notably, as shown in the murine model, CMV-specific CD8 T cells protect in an epitope-specific, T-cell receptordependent manner (1), although both viruses code for multiple glycoproteins, so-called immunoevasins, that interfere with the major histocompatibility complex (MHC) class I pathway of antigen presentation (for a review, see reference 22) . So, apparently, immunoevasins may indeed inhibit the trafficking of peptide-loaded MHC class I molecules but fail to completely prevent cell surface presentation.
While all but one of the currently known antigenic peptides of mCMV, as far as tested, mediate protection regardless of the numerical immunodominance of the cognate CD8 T cells (reviewed in reference 11), the MHC D b -presented peptide 985-HGIRNASFI-993 (10) derived from the antiapoptotic protein M45 (3), briefly named here the M45-D b peptide, is the prototype of a nonprotective mCMV epitope (16) . The reason for this exceptional position is currently unknown. It appears to result from inefficient epitope presentation by the infected cells and not from a functional deficiency of the cognate effector cells, since M45-D b epitope-specific ex vivo-sorted CD8 T cells as well as cytolytic T lymphocytes (CTL) propagated as CTL lines (CTLL) protected against infection with an mCMV mutant in which the gene encoding the major immunoevasin m152/gp40 (5, 18, 25, 31) was selectively deleted (16) . Thus, immunoevasins are causally involved in determining whether or not a particular epitope is protective, a conclusion that is of considerable relevance in the choice of epitopes for vaccines and cytoimmunotherapy. One possible explanation to be discussed is that the M45-D b complex is more efficiently retained by m152/gp40. Alternatively, inefficient generation of M45-D b complexes may facilitate a complete blockade of epitope presentation by immunoevasins, while the generation of high numbers of MHC peptide complexes might exhaust the inhibitory capacity of the immunoevasins. Here we present evidence in support of the second alternative.
Although discussed previously (5, 13), the interrelation between the efficiency of antigen processing and immunoevasin function, and its implication for peptide presentation and antiviral protection, has not been elucidated experimentally. ) is well characterized and has been reviewed recently (7, 14) .
As shown in Fig. 1B by the frequencies of the M45 peptidespecific memory CD8 T cells, the immune response to the M45-D b epitope in C57BL/6 mice is numerically higher than the response to the M45-D d epitope in BALB/c mice, both in terms of absolute frequencies (Fig. 1B, left panel) and normalized to the total reactivity measured by sensitizing CD8 T cells polyclonally through the signal-transmitting T-cell-receptorcomplex component CD3ε for gamma interferon (IFN-␥) secretion (Fig. 1B, right panel) . This normalization is important because memory cell populations still contain a majority of naive precursor cells so that only a small fraction of ex vivo-isolated CD8 T cells are capable of responding in the assay (15, 16) . So, with regard to the magnitude of the memory CD8 T-cell response, the M45-D b epitope is immunodominant, while the M45-D d epitope is subdominant. We then generated the respective epitope-specific CTLL for testing functional avidity in the cytolysis assay in vitro ( Fig. 2A) and protective activity upon adoptive transfer in vivo (Fig. 2B) . (Fig. 2B ). In conclusion, the functional avidities of the CTLL cannot explain the failure in protection by M45-D b CTL. So far in this work, peptides were loaded onto cell surface MHC class I molecules by the incubation of target cells with defined concentrations of synthetic peptide. Under infection conditions, peptide-loaded MHC class I molecules are generated within infected cells by antigen processing. This multistep process involves protein cleavage, which usually takes place in the proteasome and generates antigenic peptide precursors, the translocation of these precursors into the endoplasmic reticulum lumen via the transporter associated with antigen processing, N-terminal trimming to the final peptide size, and loading onto nascent MHC class I molecules in a specific loading complex (for reviews, see references 26 and 29). Differences in the efficacy of the processing process at any of these stages can lead to differences in the number of MHC peptide complexes generated in the infected cells. We have therefore quantitated the M45 peptides in chromatographically fractionated acidic lysates of infected cells (Fig. 3A) . Since unbound peptides are degraded, the number of peptides isolated from a cell is equivalent to the number of peptide-loaded MHC class I complexes present in the cell (5, 9) . In a first approach, antigenic peptides-and thus MHC peptide complexes-were quantitated in the absence of immunoevasin m152/gp40 after the infection of fibroblasts of the respective haplotype with the bacterial artificial chromosome-cloned deletion mutant mCMV-⌬m152 (27) . Notably, whereas ϳ1,200 M45-D d peptides per cell were recovered, infected cells contained only ϳ2 -specific CTLL were transferred intravenously into immunocompromised, infected BALB/c and C57BL/6 mice, respectively. Immunosuppressive conditioning of transfer recipients was achieved by total-body ␥-irradiation (BALB/c mice, 6 Gy at 2 h before infection; C57BL/6 mice, 7 Gy at 24 h before infection). Intraplantar infection with 10 5 PFU of mCMV wild-type virus, strain Smith, was followed by the cell transfer. Ø, no adoptive cell transfer. Infectious virus was quantitated on day 11 after transfer in lung homogenates by a virus plaque assay under conditions of centrifugal enhancement of infectivity (reference 20 and references therein). The dotted lines indicate the detection limit (DL) of the plaque assay. Dots represent results for individual mice. The median values are marked by horizontal bars. The statistical significance of differences in virus titers was evaluated by using distribution-free Wilcoxon-Mann-Whitney (rank-sum) statistics. Virus titers in two experimental groups differ significantly if the P value (by a two-tailed test) is Ͻ0.05. ) mice were infected with immunoevasin gene deletion mutant mCMV-⌬m152 or the corresponding revertant virus mCMV⌬m152-rev. At 20 h after infection, naturally processed peptides were acid extracted and separated by reversed-phase high-performance liquid chromatography (HPLC) (13) . P815 and EL-4 target cells were pulsed with the indicated volume aliquots of HPLC fractions from BALB/c MEF and C57BL/6 MEF, respectively. Lysis of target cells by the respective CTL was assayed at an effector-cell-to-target-cell (E/T) ratio of 15. The amounts of naturally processed M45 peptides were calculated by comparison with respective standard curves defined with graded molar concentrations of the corresponding synthetic peptides, which were found to coelute with the naturally processed peptides. Standard curves and their 95% confidence intervals for slope and ordinate intercept were determined by linear regression analysis. Indicated numbers of peptides per cell represent the most probable numbers, with their 95% confidence intervals given in parentheses. (B) Presentation of M45 peptides after infection of cells in the presence or absence of immunoevasin m152/gp40. (Left panels) As a control for the functional avidity of the two CTLL used as effector cells in the IFN-␥-based enzyme-linked immunospot assay, MEF derived from BALB/c or C57BL/6 mice were exogenously loaded with the indicated concentrations of the cognate synthetic M45 peptide and used as stimulator cells. Ø, no peptide added. Gray bars represent the measured cumulative avidity distributions of stimulated effector cells, whereas black bars represent the corresponding Gaussian avidity distributions mathematically deduced as described previously (2) . (Right panels) MEF derived from BALB/c or C57BL/6 mice were either not infected (n.i.) or infected with mCMV-⌬m152-rev or mCMV-⌬m152 for use as stimulator cells. Gray bars represent the frequencies of responding effector cells. Throughout, error bars indicate the upper limits of the 95% confidence intervals. (Fig. 3A , bottom panels). The increase in the extractable amount of peptide in the presence of m152/gp40 may be explained by the accumulation of MHC peptide complexes in a cis-Golgi compartment, which is the known mechanism by which m152/gp40 interferes with peptide presentation (31) .
For correlating intracellular processing with cell surface presentation in the absence and presence of the immunoevasin m152/gp40, peptide presentation was measured by the capacity of the infected cells to sensitize epitope-specific but still polyclonal M45-D d and M45-D b CTLL for IFN-␥ secretion (Fig.  3B) . For characterizing the two CTLL in this assay and with fibroblasts as the target cell type, the functional avidity distributions were determined by measuring the frequencies of effector cells sensitized by fibroblasts loaded with graded concentrations of the respective peptide (Fig. 3B, left panels) . This confirmed the avidity difference between the two CTLL in that the threshold concentration for recognition was 10 CTLL failed despite higher functional avidity but in accordance with inefficient antigen processing. In contrast, a significant number of cells in both CTLL recognized fibroblasts infected with mCMV-⌬m152 (Fig. 3B, right panels) .
Finally, we correlated the recognition of infected fibroblasts in cell culture with in vivo protection (Fig. 4) . Notably, the in vitro data for fibroblasts (Fig. 3B) were found to precisely predict protection in vivo. Specifically, M45-D d CTL protected against both mutant and revertant virus but with a dose-response efficacy that was reduced in the presence of immunoevasin m152/gp40, leading to an ϳ50-fold difference in lung virus titers after the transfer of 10 6 cells (Fig. 4, left panels) . In contrast, M45-D b CTL protected only when the immunoevasin gene was deleted (Fig. 4, right panels) .
Remarkably, a steady-state level of very few M45-D b complexes per cell led to a cell surface expression sufficient for target cell recognition and in vivo protection, provided that immunoevasin m152/gp40 was not expressed. This conclusion is not restricted to this particular M45-D b -specific CTLL but applied likewise also to M45-D b -specific memory CD8 T cells isolated ex vivo by epitope-specific cell sorting (16) . The data imply that the second immunoevasin of mCMV, namely, m06/ gp48 that redirects MHC peptide complexes to lysosomes for degradation (23) , was not sufficiently effective to block presentation. While m152/gp40 completely prevented presentation of the few M45-D b complexes, it apparently could not quantitatively cope with the ϳ1,000-fold higher number of M45-D d complexes. It has been shown previously that already a 10-fold difference in the amount of processed peptide can be decisive for target cell formation and protection (6) . The new mechanistic understanding here is that processing efficacy is critical only if immunoevasins inhibit peptide presentation.
As discussed previously, the numerical immunodominance of epitope-specific CD8 T cells does not predict protective antiviral activity (16, 17) , most likely because priming in vivo can occur through uninfected dendritic cells that cross-present viral peptides (for a review, see reference 30). In fact, immunoevasins can even promote priming as they prevent negative-feedback regulation by protecting infected cells against early CD8 T-cell control, thereby sustaining the antigen supply for cross-presentation (2). In accordance with such a mechanism, the priming of M45-D b -specific CD8 T cells was successful also in the presence of immunoevasins, whereas protection against CMV disease depends on efficient antigen processing to overcome the inhibitory function of immunoevasins.
Conclusion. These data revealed the mechanistic relationship between antigen processing and immunoevasin function in mediating or preventing antiviral protection. Whereas immunoevasins generally inhibit the transport of peptide-loaded MHC class I complexes to the cell surface, the completeness of this inhibition is critically influenced by the efficacy of antigen processing. 
